Literature DB >> 32199616

Long non-coding RNA MANCR is a target of BET bromodomain protein BRD4 and plays a critical role in cellular migration and invasion abilities of prostate cancer.

Masayuki Nagasawa1, Kosuke Tomimatsu2, Koji Terada2, Kenta Kondo2, Kazuko Miyazaki3, Masaki Miyazaki3, Daisuke Motooka4, Daisuke Okuzaki4, Tetsuya Yoshida5, Susumu Kageyama5, Hiroshi Kawamoto3, Akihiro Kawauchi5, Yasutoshi Agata6.   

Abstract

Androgen receptor (AR)-negative castration-resistant prostate cancer (CRPC) is highly aggressive and is resistant to most of the current therapies. Bromodomain and extra terminal domain (BET) protein BRD4 binds to super-enhancers (SEs) that drive high expression of oncogenes in many cancers. A BET inhibitor, JQ1, has been found to suppress the malignant phenotypes of prostate cancer cells, however, the target genes of JQ1 remain largely unknown. Here we show that SE-associated genes specific for AR-negative CRPC PC3 cells include genes involved in migration and invasion, and that JQ1 impairs migration and invasion of PC3 cells. We identified a long non-coding RNA, MANCR, which was markedly down-regulated by JQ1, and found that BRD4 binds to the MANCR locus. MANCR knockdown led to a significant decrease in migration and invasion of PC3 cells. Furthermore, RNA sequencing analysis revealed that expression of the genes involved in migration and invasion was altered by MANCR knockdown. In summary, our data demonstrate that MANCR plays a critical role in migration and invasion of PC3 cells.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BET protein inhibitor; Epithelial-mesenchymal transition; MANCR; Prostate cancer; Super-enhancer; lncRNA

Year:  2020        PMID: 32199616     DOI: 10.1016/j.bbrc.2020.03.043

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

Review 1.  Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets.

Authors:  Xuanrong Chen; Qianwang Ma; Zhiqun Shang; Yuanjie Niu
Journal:  NPJ Precis Oncol       Date:  2020-11-19

2.  Effects of activation of the LINE-1 antisense promoter on the growth of cultured cells.

Authors:  Tomoyuki Honda; Yuki Nishikawa; Kensuke Nishimura; Da Teng; Keiko Takemoto; Keiji Ueda
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

Review 3.  Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance.

Authors:  Guo-Hua Li; Qiang Qu; Ting-Ting Qi; Xin-Qi Teng; Hai-Hong Zhu; Jiao-Jiao Wang; Qiong Lu; Jian Qu
Journal:  J Exp Clin Cancer Res       Date:  2021-05-19

4.  Systematic Analysis of Long Non-Coding RNA Genes in Nonalcoholic Fatty Liver Disease.

Authors:  Mirolyuba Ilieva; James Dao; Henry E Miller; Jens Hedelund Madsen; Alexander J R Bishop; Sakari Kauppinen; Shizuka Uchida
Journal:  Noncoding RNA       Date:  2022-07-22

5.  Long-Noncoding RNA MANCR is Associated With Head and Neck Squamous Cell Carcinoma Malignant Development and Immune Infiltration.

Authors:  Jianfei Tang; Mingyan Bao; Juan Chen; Xin Bin; Xinghuanyu Xu; Xiaodan Fang; Zhangui Tang
Journal:  Front Genet       Date:  2022-07-08       Impact factor: 4.772

6.  Modulation of macrophage inflammatory function through selective inhibition of the epigenetic reader protein SP140.

Authors:  Nicola R Harker; David F Tough; Wouter J de Jonge; Mohammed Ghiboub; Jan Koster; Peter D Craggs; Andrew Y F Li Yim; Anthony Shillings; Sue Hutchinson; Ryan P Bingham; Kelly Gatfield; Ishtu L Hageman; Gang Yao; Heather P O'Keefe; Aaron Coffin; Amish Patel; Lisa A Sloan; Darren J Mitchell; Thomas G Hayhow; Laurent Lunven; Robert J Watson; Christopher E Blunt; Lee A Harrison; Gordon Bruton; Umesh Kumar; Natalie Hamer; John R Spaull; Danny A Zwijnenburg; Olaf Welting; Theodorus B M Hakvoort; Anje A Te Velde; Johan van Limbergen; Peter Henneman; Rab K Prinjha; Menno P J de Winther
Journal:  BMC Biol       Date:  2022-08-19       Impact factor: 7.364

7.  Identification of a combined lncRNA prognostic signature and knockdown of lncRNA MANCR to inhibit progression of clear cell renal cell carcinoma by bioinformatics analysis.

Authors:  Sheng Xue; Hanxu Guo; Shibo Wei; Yuan Song; Junfeng Huang; Shuo Deng; Qingwen Li; Wenyong Li
Journal:  Transl Androl Urol       Date:  2022-09

Review 8.  Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer.

Authors:  Shangwei Zhong; Shoujiao Peng; Zihua Chen; Zhikang Chen; Jun-Li Luo
Journal:  Pharmaceutics       Date:  2022-02-24       Impact factor: 6.321

9.  An immune-related lncRNA signature for the prognosis of pancreatic adenocarcinoma.

Authors:  Bing Qi; Han Liu; Qi Zhou; Li Ji; Xueying Shi; Yushan Wei; Yajun Gu; Akio Mizushima; Shilin Xia
Journal:  Aging (Albany NY)       Date:  2021-07-20       Impact factor: 5.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.